# US 2010/0062471 A1 · Biomarkers for Multiple Sclerosis and Methods of Use Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0062471 A1
- Document ID: US20100062471A1
- Status: Published application
- Kind: A1
- Application number: 12/088,228
- Filed: 2006-09-29
- Published: 2010-03-11
- Earliest claimed: 2005-09-29
- Assignees: PPD Biomarker Discovery Sciences, LLC; Biogen Idec MA Inc.
- Inventors: Aaron B. Kantor; Susan Goelz; Jun Deng; Hua Lin; Christopher Becker
- Web page: https://patentgrep.com/patent/US20100062471A1

## CPC

- G01N 33/5091: {for testing the pathological state of an organism}
- G01N 33/5008: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics}
- G01N 33/5023: {on expression patterns}
- G01N 33/5047: {Cells of the immune system}
- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 2500/00: Screening for compounds of potential therapeutic value
- G01N 2500/10: involving cells
- G01N 2800/285: Demyelinating diseases; Multipel sclerosis
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Biomarkers useful for identifying treatments for and monitoring treatment of patients with multiple sclerosis (MS) are provided, as well as methods for their identification, methods of diagnosing MS, relapse of MS patients and disease progression in MS patients.

## Claims

### Claim 1

A method to identify a composition useful for the treatment of multiple sclerosis in a subject, comprising:
a) administering a test composition to the subject,
b) evaluating whether administration of the test composition causes a transient change in a biomarker selected from the group consisting of a monocyte-associated variable, IP-10, IL-1RA, IL-18 binding protein, β-NGF, BDNF, CRP, ACT, ceruloplasmin, haptoglobin, alpha-1-acid glycoprotein, orosomucoid, serum amyloid A, a complement cascade component, VCAM, MMP, and LIF; wherein a transient change in the biomarker indicates the test composition is useful for treatment of multiple sclerosis.

### Claim 2 (depends on 1)

The method, as claimed in claim 1, wherein the transient change in the biomarker is an increase and occurs within about 1 to about 2 days after administration of the test composition.

### Claim 3 (depends on 1)

The method, as claimed in claim 1, wherein the transient change in the biomarker is reversed at about 6 days after administration of the test composition.

### Claim 4 (depends on 1)

The method, as claimed in claim 1, wherein the biomarker is a monocyte-associated variable.

### Claim 5 (depends on 4)

The method, as claimed in claim 4, wherein the-monocyte-associated variable is selected from the group consisting of absolute monocyte count; monocyte/leukocyte ratio; monocyte expression of a protein selected from the group consisting of HLA Class II, CCR5, CD11b, CD38, CD40, CD54, CD64, CD69, CD86, TLR2, or TLR4; and MCP2 (monocyte chemoattractant protein 2).

### Claim 6 (depends on 5)

The method, as claimed in claim 5, wherein the monocyte-associated variable is absolute monocyte count.

### Claim 7 (depends on 5)

The method, as claimed in claim 5, wherein the monocyte-associated variable is monocyte/leukocyte ratio.

### Claim 8 (depends on 7)

The method, as claimed in claim 7, wherein the increase is at least about 50%.

### Claim 9 (depends on 7)

The method, as claimed in claim 7, wherein the increase is between about 50% and about 75%.

### Claim 10 (depends on 5)

The method, as claimed in claim 5, wherein the monocyte-associated variable is monocyte expression of HLA Class II.

### Claim 11 (depends on 10)

The method, as claimed in claim 10, wherein the increase is at least about 30%.

### Claim 12 (depends on 10)

The method, as claimed in claim 10, wherein the increase is between about 30% and about 120%.

### Claim 13 (depends on 1)

The method, as claimed in claim 1, further comprising evaluating whether administration of the test composition causes a transient change in two or more of the biomarkers.

### Claim 14 (depends on 1)

The method, as claimed in claim 1, further comprising evaluating whether administration of the test composition causes a transient change in three or more of the biomarkers.

### Claim 15 (depends on 1)

The method, as claimed in claim 1, further comprising evaluating whether administration of the test composition causes a transient change in four or more of the biomarkers.

### Claim 16 (depends on 1)

The method, as claimed in claim 1, wherein the subject is selected from the group consisting of human, non-human primates, and rodents.

### Claim 17 (depends on 16)

The method, as claimed in claim 16, wherein the subject is human.

### Claim 18 (depends on 17)

The method, as claimed in claim 17, wherein the subject is selected from the group consisting of a Healthy subject, a Naïve subject, and a subject on an established IFN-beta treatment.

### Claim 19

A method to identify a dose of a composition, useful for the treatment of multiple sclerosis in a subject, to elicit a desired magnitude of response; comprising:
a) administering the composition to subjects at different doses, wherein the composition causes a transient change in a biomarker selected from the group consisting of a monocyte-associated variable, IP-10, IL-1RA, IL-18 binding protein, β-NGF, BDNF, CRP, ACT, ceruloplasmin, haptoglobin, alpha-1-acid glycoprotein, orosomucoid, serum amyloid A, a complement cascade component, VCAM, MMP, and LIF;
b) evaluating the change in the biomarker at the different doses of the composition; and
c) identifying a dose of the composition that elicits the desired magnitude of response in at least one of the biomarkers.

### Claim 20 (depends on 19)

The method, as claimed in claim 19, wherein the biomarker is a monocyte-associated variable.

### Claim 21 (depends on 20)

The method, as claimed in claim 20, wherein the monocyte-associated variable is selected from the group consisting of absolute monocyte count; monocyte/leukocyte ratio; monocyte expression of a protein selected from the group consisting of HLA Class II, CCR5, CD11b, CD38, CD40, CD54, CD64, CD69, CD86, TLR2, or TLR4; and MCP2 (monocyte chemoattractant protein 2).

### Claim 22 (depends on 21)

The method, as claimed in claim 21, wherein the monocyte-associated variable is absolute monocyte count.

### Claim 23 (depends on 21)

The method, as claimed in claim 21, wherein the monocyte-associated variable is monocyte/leukocyte ratio.

### Claim 24 (depends on 23)

The method, as claimed in claim 23, wherein the desired magnitude of response is an increase of at least about 50%.

### Claim 25 (depends on 23)

The method, as claimed in claim 23, wherein the desired magnitude of response is an increase of between about 50% and about 75%.

### Claim 26 (depends on 21)

The method, as claimed in claim 21, wherein the monocyte-associated variable is monocyte expression of HLA Class II.

### Claim 27 (depends on 26)

The method, as claimed in claim 26, wherein the desired magnitude of response is an increase of at least about 30%.

### Claim 28 (depends on 26)

The method, as claimed in claim 26, wherein the desired magnitude of response is an increase of between about 30% and about 120%.

### Claim 29 (depends on 19)

The method, as claimed in claim 19, further comprising evaluating whether administration of the composition causes a transient change in two or more of the biomarkers.

### Claim 30 (depends on 19)

The method, as claimed in claim 19, further comprising evaluating whether administration of the composition causes a transient change in three or more of the biomarkers.

### Claim 31 (depends on 19)

The method, as claimed in claim 19, further comprising evaluating whether administration of the composition causes a transient change in four or more of the biomarkers.

### Claim 32 (depends on 19)

The method, as claimed in claim 19, wherein the subject is selected from the group consisting of human, non-human primates, and rodents.

### Claim 33 (depends on 32)

The method, as claimed in claim 32, wherein the subject is human.

### Claim 34 (depends on 33)

The method, as claimed in claim 33, wherein the subject is selected from the group consisting of a Healthy subject, a Naïve subject, and a subject on established IFN-beta treatment.

### Claim 35

A method to monitor treatment of a subject for multiple sclerosis, comprising:
a) administering a therapeutic composition to the subject,
b) evaluating whether administration of the therapeutic composition causes a transient change in a biomarker selected from the group consisting of a monocyte-associated variable, IP-10, IL-1RA, IL-18 binding protein, β-NGF, BDNF, CRP, ACT, ceruloplasmin, haptoglobin, alpha-1-acid glycoprotein, orosomucoid, serum amyloid A, a complement cascade component, VCAM, MMP, and LIF; wherein a transient change in the biomarker indicates efficacious treatment of multiple sclerosis.

### Claim 36 (depends on 35)

The method, as claimed in claim 35, wherein the transient change in the biomarker is an increase and occurs within about 1 to about 2 days after administration of the therapeutic composition.

### Claim 37 (depends on 35)

The method, as claimed in claim 35, wherein the transient change in the biomarker is reversed at about 6 days after administration of the test composition

### Claim 38 (depends on 35)

The method, as claimed in claim 35, wherein the biomarker is a monocyte-associated variable.

### Claim 39 (depends on 38)

The method, as claimed in claim 38, wherein the monocyte-associated variable is selected from the group consisting of absolute monocyte count; monocyte/leukocyte ratio; monocyte expression of a protein selected from the group consisting of HLA Class II, CCR5, CD11b, CD38, CD40, CD54, CD64, CD69, CD86, TLR2, or TLR4; and MCP2 (monocyte chemoattractant protein 2).

### Claim 40 (depends on 38)

The method, as claimed in claim 38, wherein the monocyte-associated variable is absolute monocyte count.

### Claim 41 (depends on 38)

The method, as claimed in claim 38, wherein the monocyte-associated variable is monocyte/leukocyte ratio.

### Claim 42 (depends on 41)

The method, as claimed in claim 41, wherein the increase is at least about 50%.

### Claim 43 (depends on 41)

The method, as claimed in claim 41, wherein the increase is between about 50% and about 75%.

### Claim 44 (depends on 38)

The method, as claimed in claim 38, wherein the monocyte-associated variable is monocyte expression of HLA Class II.

### Claim 45 (depends on 44)

The method, as claimed in claim 44, wherein the increase is at least about 30%.

### Claim 46 (depends on 44)

The method, as claimed in claim 44, wherein the increase is between about 30% and about 120%.

### Claim 47 (depends on 35)

The method, as claimed in claim 35, further comprising evaluating whether administration of the composition causes a transient change in two or more of the biomarkers.

### Claim 48 (depends on 35)

The method, as claimed in claim 35, further comprising evaluating whether administration of the composition causes a transient change in three or more of the biomarkers.

### Claim 49 (depends on 35)

The method, as claimed in claim 35, further comprising evaluating whether administration of the composition causes a transient change in four or more of the biomarkers.

### Claim 50 (depends on 35)

The method, as claimed in claim 35, wherein the subject is selected from the group consisting of human, non-human primates, and rodents.

### Claim 51 (depends on 50)

The method, as claimed in claim 50, wherein the subject is human.

### Claim 52 (depends on 51)

The method, as claimed in claim 51, wherein the subject is selected from the group consisting of a Healthy subject, a Naïve subject, and a subject on established IFN-beta therapy.

### Claim 53

A method to identify a composition useful for the treatment of multiple sclerosis in a subject, comprising:
a) administering a test composition to a subject;
b) evaluating whether the test composition causes a change in at least one of the following biomarkers on a long term basis: decreased NK cell counts; increased CD56 expression on NK cells; increased MCP2 expression; decreased CD8 T cell counts; normal B cell counts; redistribution of naïve and memory CD4 and CD8 T cell subsets compared to Naïve subjects; decreased Apo H; decreased inter-alpha globulin inhibitor H1; decreased complement component C1s; increased complement component C2; increased Mac2 binding; decreased attractin-2; reduced B cell counts; reduced expression of CD38 on B cells; increased expression of NKB1 on NK cells; increased IFNγ and IL-2 in CD8 cells following ex vivo stimulation; increased IL-2 production in CD4 T cells following ex vivo stimulation; redistribution of naïve and memory T cell subsets; increased soluble CD14; increased soluble VCAM; reduced MIP-1a; reduced IL-6R; reduced MCP-1; increased MxA; increased IP-10, decreased MIP-1-β; increased β-NGF; increased complement component C1s, increased complement component C1q; increased prothrombin; increased α-1 antichymotrypsin; decreased CALNUC; increased gelsolin; increased alpha-2 plasmin inhibitor; decreased fetuin-A; and decreased AMBP; wherein a change of one or more of the biomarkers indicates that the test composition is useful for treatment of multiple sclerosis.

### Claim 54

A method to identify a dose of a composition, useful for the treatment of multiple sclerosis in a subject, to elicit a desired magnitude of response, comprising:
a) administering a composition to subjects at different doses, wherein the composition causes a change in at least one of the following biomarkers on a long term basis: decreased NK cell counts; increased CD56 expression on NK cells; increased MCP2 expression; decreased CD8 T cell counts; normal B cell counts; redistribution of naïve and memory CD4 and CD8 T cell subsets compared to Naïve subjects; decreased Apo H; decreased inter-alpha globulin inhibitor H1; decreased complement component C1s; increased complement component C2; increased Mac2 binding; decreased attractin-2; reduced B cell counts; reduced expression of CD38 on B cells; increased expression of NKB1 on NK cells; increased IFNγ and IL-2 in CD8 cells following ex vivo stimulation; increased IL-2 production in CD4 T cells following ex vivo stimulation; redistribution of naïve and memory T cell subsets; increased soluble CD14; increased soluble VCAM; reduced MIP-1a; reduced IL-6R; reduced MCP-1; increased MxA; increased IP-10, decreased MIP-1-β; increased β-NGF; increased complement component C1s, increased complement component C1q; increased prothrombin; increased α-1 antichymotrypsin; decreased CALNUC; increased gelsolin; increased alpha-2 plasmin inhibitor; decreased fetuin-A; and decreased AMBP;
b) evaluating the change in the biomarker at the different doses of the composition; and
c) identifying a dose of the composition that elicits the desired magnitude of response in at least one of the biomarkers.

### Claim 55

A method to monitor treatment of a subject for multiple sclerosis, comprising:
a) administering a therapeutic composition to the subject,
b) evaluating whether administration of the therapeutic composition causes a change in at least one of the following biomarkers on a long term basis: decreased NK cell counts; increased CD56 expression on NK cells; increased MCP2 expression; decreased CD8 T cell counts; normal B cell counts; redistribution of naïve and memory CD4 and CD8 T cell subsets compared to Naïve subjects; decreased Apo H; decreased inter-alpha globulin inhibitor H1; decreased complement component C1s; increased complement component C2; increased Mac2 binding; decreased attractin-2; reduced B cell counts; reduced expression of CD38 on B cells; increased expression of NKB1 on NK cells; increased IFNγ and IL-2 in CD8 cells following ex vivo stimulation; increased IL-2 production in CD4 T cells following ex vivo stimulation; redistribution of naïve and memory T cell subsets; increased soluble CD14; increased soluble VCAM; reduced MIP-1a; reduced IL-6R; reduced MCP-1; increased MxA; increased IP-10, decreased MIP-1-β; increased β-NGF; increased complement component C1s, increased complement component C1q; increased prothrombin; increased α-1 antichymotrypsin; decreased CALNUC; increased gelsolin; increased alpha-2 plasmin inhibitor; decreased fetuin-A; and decreased AMBP; wherein a long-term change in the biomarker indicates efficacious treatment of multiple sclerosis.

### Claim 56

A method to diagnose a subject as having multiple sclerosis, comprising:
a) analyzing a subject sample for at least one of the following biomarkers:
i. reduced B cell counts;
ii. reduced expression of CD38 on B cells;
iii. increased expression of NKB1 on NK cells;
iv. increased IFNγ and IL-2 in CD8 T cells following ex vivo stimulation;
v. increased IL-2 production in CD4 T cells following ex vivo stimulation;
vi. redistribution of naïve and memory T cell subsets;
vii. increased soluble CD14;
viii. increased soluble VCAM;
ix. reduced MIP-1a;
x. reduced IL-6R;
xi. reduced MCP-1
b) diagnosing multiple sclerosis, wherein the presence of one or more of (a)(i)-(a)(xi) indicates the subject has multiple sclerosis.

### Claim 57 (depends on 56)

The method, as claimed in claim 56, wherein biomarkers (a)(i)-(a)(xi) are determined by comparison with a sample of a subject known not to have multiple sclerosis.

### Claim 58 (depends on 56)

The method, as claimed in claim 56, wherein the sample is selected from the group consisting of a urine sample, a serum sample and a cerebrospinal fluid.

### Claim 59 (depends on 56)

The method, as claimed in claim 56, further comprising analyzing two or more of the biomarkers.

### Claim 60 (depends on 56)

The method, as claimed in claim 56, further comprising analyzing three or more of the biomarkers.

### Claim 61 (depends on 56)

The method, as claimed in claim 56, further comprising analyzing four or more of the biomarkers.

### Claim 62

A method to diagnose relapse or disease progression in a subject having multiple sclerosis that is being treated for multiple sclerosis, comprising:
a) analyzing a subject sample for at least one of the following biomarkers:
i. increased MxA;
ii. increased IP-10
iii. decreased MIP-1-β
iv. increased β-NGF;
v. increased complement component C1s;
vi. increased complement component C1q;
vii. increased prothrombin;
viii. increased soluble VCAM;
ix. increased α-1 antichymotrypsin;
x. decreased CALNUC;
xi. increased gelsolin;
xii. increased alpha-2 plasmin inhibitor;
xiii. decreased fetuin-A;
xiv. decreased AMBP;
b) diagnosing relapse or disease progression, wherein the presence of one or more of (a)(i)-(a)(xiv) indicates the subject is in relapse or has disease progression.

### Claim 63 (depends on 62)

The method, as claimed in claim 62, wherein the subject is being treated by the administration of interferon.

### Claim 64 (depends on 62)

The method, as claimed in claim 62, wherein the interferon is IFN-β-1a.

### Claim 65 (depends on 62)

The method, as claimed in claim 62, wherein biomarkers(a)(i)-(a)(xiv) are determined by comparison with a sample of a multiple sclerosis subject being successfully treated.

### Claim 66 (depends on 62)

The method, as claimed in claim 62, wherein the sample is selected from the group consisting of a urine sample, a serum sample and a cerebrospinal fluid sample.

### Claim 67 (depends on 62)

The method, as claimed in claim 62, further comprising analyzing two or more of the biomarkers.

### Claim 68 (depends on 62)

The method, as claimed in claim 62, further comprising analyzing three or more of the biomarkers.

### Claim 69 (depends on 62)

The method, as claimed in claim 62, further comprising analyzing four or more of the biomarkers.

### Claim 70 (depends on 35)

The method, as claimed in claim 35, further comprising evaluating whether the magnitude of the transient change decreases over time, wherein a decrease is predictive of relapse.
